[go: up one dir, main page]

EP1633742A1 - Derives d'indol en tant qu'inhibiteurs de reapsorption de la serotonine - Google Patents

Derives d'indol en tant qu'inhibiteurs de reapsorption de la serotonine

Info

Publication number
EP1633742A1
EP1633742A1 EP04734520A EP04734520A EP1633742A1 EP 1633742 A1 EP1633742 A1 EP 1633742A1 EP 04734520 A EP04734520 A EP 04734520A EP 04734520 A EP04734520 A EP 04734520A EP 1633742 A1 EP1633742 A1 EP 1633742A1
Authority
EP
European Patent Office
Prior art keywords
disorders
derivatives
formula
solvates
mixtures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04734520A
Other languages
German (de)
English (en)
Inventor
Timo Heinrich
Henning Böttcher
Kai Schiemann
Günter Hölzemann
Christoph Van Amsterdam
Gerd Bartoszyk
Joachim Leibrock
Christoph Seyfried
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of EP1633742A1 publication Critical patent/EP1633742A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Definitions

  • the present invention relates to new indole derivatives, processes for their preparation and use of the compounds for the manufacture of medicaments for the treatment and prophylaxis of diseases which are related to serotonin reuptake and / or serotonin receptors (serotonin, 5-hydroxytryptamine, 5- HT).
  • 5-HT receptor The following types of 5-HT receptor are known, for example: 5-HTIA, 5-HT-IB, 5-HTID, 5-HT 2Al 5-HT 2B , 5-HT 2C , 5-HT 3 , 5-HT 4 ( 5-HT 6 , 5-HT 7.
  • 5-HT-iD ⁇ and 5-HT-iDß which differ in tissue specificity, mode of action and other properties.
  • EP0655442 describes piperazine derivatives with a tachykinin-antagonistic effect.
  • Indole piperazine derivatives are known from EP0648767, US5532241, EP0407844, EP0376607, BE771285, GB1075156, GB118064, FR1551082 and from EP 0 736 525. These compounds are effective serotonin reuptake inhibitors and 5-HT- A receptor agonists.
  • indole piperidine and indole piperazine derivatives are known which are effective 5-HT 1D ⁇ receptor agonists .
  • the connections disclosed therein are based on their vasoconstrictive effect used to treat diseases related to migraines.
  • the invention was based on the task of finding new compounds which can be used for the production of medicaments.
  • Compounds of formula 1 have effects on the central nervous system. They act as selective serotonin reuptake inhibitors, show serotonin agonistic and antagonistic properties and thus influence serotoninergic transmission. In particular, they show 5-HT-i A agonistic effects and an affinity for the serotoin receptor subtype 5-HT4.
  • the invention therefore relates to compounds of the formula I.
  • a and B are preferably unbranched independently of one another and have 1, 2, 3, 4, 5 or 6 carbon atoms.
  • Alkyl with 1-6 C atoms preferably means methyl, ethyl, n-propyl, further preferably isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, but also n-pentyl, neopentyl, isopentyl or n- hexyl.
  • Alkaryl means alkyl with 1-6 C atoms connected with an aromatic ring system of 6 or 10 centers such as e.g. B. benzyl or phenethyl.
  • Alkheteroaryl means alkyl with 1-6 C atoms combined with an aromatic heterocycle from 5, 6 or 10 centers such as.
  • Heteroaryl means a monovalent monocyclic or bicyclic heterocycle with 5-12 ring atoms, which has at least one aromatic ring, 1, 2 or 3 ring atoms being selected from N, O or S. Heteroaryl is optionally independently substituted with 1-4 substituents, for example selected from alkyl, cycloalkyl.cycloalkylalkyl, shark, NO, CN, alkoxy, NH 2 , acylamino, monoalkylamino, dialkylamino, haloalkyl, haloalkoxy or heteroalkyl.
  • heteroaryls are pyridyl, furanyl, thienyl, Thiazolyl, isothiazolyl, triazolyl, imidazolyl, isoxazolyl, pyrrolyl, Pyrazoiyl, pyrazinyl, pyrimidinyl, benzofuranyl, tetrahydrobenzofuranyl, isobenzofuranyl, benzothiazolyl, benzoisothiazolyl, benzotriazolyl, indolyl, isoindolyl, benzoxazolyl, quinolyl, tetrahydroquinolyl, isoquinolyl, benzoimidazolyl, benzisoxazolyl or benzothienyl and derivatives from that.
  • R 4 OH, NH 2 , NHB or NB 2 ,
  • the invention also relates to the optically active forms (stereoisomers), the enantiomers, the racemates, the diastereomers and hydrates and solvates of these compounds.
  • compositions are understood to mean e.g. Salts of the compounds according to the invention, as well as so-called prodrug compounds.
  • Prodrug connections mean e.g. Alkyl or acyl groups, sugars or oligopeptides modified compounds of formula I, which are quickly split or released in the organism to the active compounds of the invention.
  • This also includes biodegradable polymer derivatives of the compounds according to the invention, such as e.g. in Int. J. Pharm. 115 (1995), 61-67.
  • Suitable acid addition salts are inorganic or organic salts of all physiologically or pharmacologically acceptable acids, for example halides, in particular hydrochlorides or
  • Solvates of the compounds of the formula I are understood to mean the addition of inert solvent molecules to the compounds of the formula I, which are formed on account of their mutual attraction. Solvates are, for example, hydrates, such as monohydrates or
  • the invention also relates to mixtures of the compounds of the formula I according to the invention, e.g. Mixtures of two diastereomers e.g. in a ratio of 1: 1, 1: 2, 1: 3, 1: 4, 1: 5, 1: 10, 1: 100 or 1: 1000. Mixtures of two stereoisomeric compounds are particularly preferred.
  • the invention also relates to a process for the preparation of the compounds of the formula I, characterized in that
  • R 2 has the meanings given above and Z represents a leaving group known to the person skilled in the art, such as, for example, p-tosyl, trifluoromethanesulfonyl,
  • the starting compounds of the formula II, III, VI and V are generally known. If they are new, they can be manufactured according to methods known per se. If desired, the starting materials can also be formed in situ, so that they are not isolated from the reaction mixture, but instead are immediately converted further into the compounds of the formula I.
  • the starting materials can be combined (fused) in a sealed reaction vessel or in an autoclave. However, it is also possible to react the starting materials in the presence of an inert solvent.
  • Suitable inert solvents are e.g. Heptane, hexane, petroleum ether, benzene, toluene, xylene, trichlorethylene, 1,2-dichloroethane tetrachloromethane, chloroform or dichloromethane; Alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; Ethers such as diethyl ether, diisopropyl ether (preferred for the substitution on
  • Glycol ethers such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or ethyl glycol), ethylene glycol dimethyl ether (diglyme); Ketones such as acetone or butanone; Amides such as acetamide, dimethylacetamide, N-methylpyrrolidone (NMP) or dimethylformamide (DMF); Nitriles such as acetonitrile; Esters like
  • Ethyl acetate carboxylic acids or acid anhydrides, such as. B. such as acetic acid or acetic anhydride, nitro compounds such as nitromethane or nitrobenzene, optionally also mixtures of the solvents mentioned with one another or mixtures with water.
  • the reaction can also be carried out in a heterogeneous phase, an aqueous phase and a benzene or toluene phase being preferably used.
  • a phase transfer catalyst such as tetrabutylammonium iodide and optionally an acylation catalyst such as dimethylaminopyridine are used.
  • the amount of solvent is not critical, preferably 10 g to 500 g of solvent can be added per g of the compound of formula I to be reacted.
  • an organic base such as, for example, triethylamine, dimethylamine, pyridine or quinoline, or an excess of the amine component.
  • Suitable reaction temperatures are from 10 to 180 ° C., preferably from 20 to 150 ° C. and very particularly preferably from 40 to 100 ° C.
  • Is preferably carried out at a pressure of 1 to 200 bar and at temperatures between -80 ° and + 150 ° C, particularly preferably at room temperature and normal pressure. Preferably at 1.5 to 120 bar and in particular at 2 to 100 bar.
  • a pH of 6 to 10 is preferred.
  • the duration of the reaction depends on the reaction conditions chosen. As a rule, the reaction time is 0.5 hours to 10 days, preferably 1 to 24 hours. When using a microwave, the response time can be reduced to 1 to 60 minutes.
  • An acid of the formula I can be converted with a base into the associated addition salt, for example by reacting equivalent amounts of the acid and the base in an inert solvent such as ethanol and including evaporation.
  • Bases that provide physiologically acceptable salts are particularly suitable for this implementation.
  • the acid of formula I can be converted with a base (e.g. sodium or potassium hydroxide or carbonate) into the corresponding metal, in particular alkali or alkaline earth metal or into the corresponding ammonium salt.
  • Organic bases that provide physiologically acceptable salts such as e.g. Ethanolamine.
  • a base of formula I can be converted into the associated acid addition salt with an acid, for example by reacting equivalent amounts of the base and the acid in an inert solvent such as ethanol and then evaporating them.
  • acids that provide physiologically acceptable salts are suitable for this implementation.
  • inorganic acids can be used, for example sulfuric acid, nitric acid, hydrohalic acids such as hydrochloric acid or hydrobromic acid, phosphoric acids such as orthophosphoric acid, sulfamic acid, ferric organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocyclic, mono- or polybasic carbon, sulfonic or Sulfuric acids, e.g.
  • the compounds of the formula I and their physiologically acceptable acid addition salts are well tolerated and have valuable pharmacological properties because they have particular effects on the central nervous system. In particular, they inhibit 5-HT reuptake.
  • the compounds also have a high affinity for the 5-HT x receptor (for 5-HT x means X: 1A or 4) and show serotonin agonistic and antagonistic properties. Through a 5-HT agonistic effect and a 5-HT reuptake inhibition, serotonin remains longer in the synaptic cleft and the serotonin effect is enhanced. Active ingredients with such properties are therefore particularly suitable as antidepressants and anxiolytics.
  • the compounds of formula I inhibit the binding of tritiated serotonin ligands to hippocampal receptors (Cossery et al., European J. Pharmacol. 140 (1987), 143-155) and the synaptosomal
  • Serotonin reuptake inhibition can also help the Waldmeier method can be examined ex vivo in the brain tissue of the mouse (European J. Pharmacol. 1977, 46, 387-92), and by the microdialysis described by DiChiara (Trends in Pharmacol. Sei., ü (1990), 116- 121).
  • a physiological solution is perfused through a microdialysis container implanted in a rat brain.
  • the solution picks up the neurotransmitters released in the brain and is subsequently analyzed.
  • the 5-HT content in the solution after perfusion is proportional to the amount released in the brain and it increases, for example, after administration of a 5-HT reuptake inhibitor (Gardier et al., Fundam. Clin. Pharmacol., 10 (1996), 16-27).
  • the 5-HTi A agonistic effect can be measured in vitro, for example using the (serotonin) binding test, as described by Matzen et al. (J. Med. Chem., 43 (2000), 1149-57), in particular on page 1156 with reference to Eur. J. Pharmacol., 140 (1987), 143-155.
  • the 5-HT-i A agonistic effect can be achieved using the method described by Newman-Tancredi et al. (Eur. J. Pharmacol. 307 (1996), 107-11) described GTPgammaS tests.
  • the invention relates in particular to the use of the compounds of the formula I and their physiologically acceptable salts, derivatives, solvates and stereoisomers, including their mixtures in all ratios as serotonin receptor ligands and / or for serotonin reuptake inhibition.
  • the use of the compounds of the formula I as 5-HT 1A agonists and as inhibitors of 5-HT reuptake is according to the invention.
  • the invention thus relates in particular to the use of compounds of the formula I and / or their physiologically acceptable salts, derivatives, solvates and stereoisomers, including their mixtures in all proportions, for the manufacture of a medicament for the treatment of diseases, in particular diseases associated with the Serotonin receptor and / or serotonin reuptake related.
  • Compounds of formula I according to the invention can be chiral due to their molecular structure and can accordingly occur in various enantiomeric forms. They can therefore be in racemic or optically active form. Since the pharmaceutical activity of the racemates or the stereoisomers of the compounds according to the invention can differ, it may be desirable to use the enantiomers. In this case, the end product or even the intermediates can be separated into enantiomeric compounds by chemical or physical measures known to the person skilled in the art, or can already be used as such in the synthesis.
  • compounds of the formula I inhibit serotonin reuptake and at the same time have 5-HTi A agonistic properties, they are particularly suitable as antidepressants and anxiolytics.
  • the invention therefore also relates to the use of compounds of the formula I and / or their physiologically acceptable salts, derivatives, solvates and stereoisomers, including their mixtures in all proportions for the manufacture of a medicament as an anxiolytic, antidepressant, neuroleptic and / or antihypertensive and / or to positively influence compulsive behavior (OCD), sleep disorders, tardive dyskinesias, learning disorders, age-related memory disorders, eating disorders such as bulimia or IBS and / or sexual dysfunction.
  • OCD compulsive behavior
  • sleep disorders tardive dyskinesias
  • learning disorders learning disorders
  • age-related memory disorders eating disorders such as bulimia or IBS and / or sexual dysfunction.
  • eating disorders such as bulimia or IBS and / or sexual dysfunction.
  • Formula I can also be used as intermediates for the preparation of other active pharmaceutical ingredients.
  • the compounds of the formula I are suitable both in veterinary and in human medicine for the treatment of functional disorders of the central nervous system and of inflammation.
  • the invention thus relates to the use of compounds of the formula I and / or their physiologically acceptable salts, derivatives, solvates and stereoisomers, including their mixtures in all proportions for the manufacture of a medicament for the treatment of psychoses, schizophrenia, schizoaffective psychosis, cyclothymia, epilepsy, Convulsions, depression (subtypes of severe depression and cyclothymic depression), pathological anxiety (subtypes of panic attacks with or without agoraphobia), overexcitation, hyperactivity, stress disorders, post-traumatic stress disorders, sleep disorders, narcolepsy, cyclical manic depressive disorders, attention disorders in children and adolescents, profound developmental disorders and disorders of social behavior with mental retardation, obsessive-compulsive illnesses (OCD) and wider senses (OCSD), addictions, disorders in food intake or eating disorders, for example Bulimi e, obesity or anorexia nervosa, especially irritable bowl syndrome (IBS), fibromyalgia, as well as
  • Parkinson's disease Alzheimer's disease, Huntington's disease, lathyrism, amyotrophic lateral sclerosis, Lewy body dementia, Tourette syndrome, sexual dysfunction, premenstrual syndrome, acromegaly, hypogonadism, secondary amenorrhea, unwanted puerperal lactation, extrapyramidal
  • Movement disorders for the treatment of side effects that occur in the treatment of extrapyramidal movement disorders with conventional anti-Parkinson medication and of extrapyramidal symptoms (EPS), states of tension, side effects of hypertension treatment that are induced by neuroleptics (e.g. with ⁇ -methyldopa) or for Prophylaxis, treatment and control of cerebral infarction (apoplexia cerebri), such as stroke and cerebral ischemia or for the treatment of pain, in particular chronic pain, migraine, CNS trauma, hypoglycemia, asthma, glaucoma, cytomegaly and for the treatment of other degenerative retinal diseases, incontinence , Tinnitus, or to treat hearing loss induced by aminoglycoside antibiotics.
  • neuroleptics e.g. with ⁇ -methyldopa
  • Prophylaxis e.g. with Prophylaxis
  • apoplexia cerebri e.g. with ⁇ -methyldopa
  • apoplexia cerebri e
  • the compounds of the formula I can be used for the production of pharmaceutical preparations, in particular by a non-chemical route. Here, they are brought into a suitable dosage form together with at least one solid, liquid and / or semi-liquid carrier or auxiliary and, if appropriate, in combination with one or more further active ingredient (s).
  • the invention therefore furthermore relates to pharmaceutical preparations containing at least one compound of the formula I and / or its physiologically acceptable salts, derivatives, solvates and stereoisomers, including their mixtures in all ratios.
  • the invention also relates in particular to those pharmaceutical preparations which contain further carriers and / or auxiliaries, and also to those pharmaceutical preparations which contain at least one further active pharmaceutical ingredient.
  • the invention in particular also relates to a process for the preparation of a pharmaceutical preparation, characterized in that a compound of the formula I and / or one of its physiologically acceptable salts, derivatives, solvates and stereoisomers, including their mixtures in all proportions together with a solid , liquid or semi-liquid carrier or auxiliary and optionally with a further active pharmaceutical ingredient in a suitable dosage form.
  • the pharmaceutical preparations according to the invention can be used as medicaments in human or veterinary medicine.
  • Suitable carrier substances are organic or inorganic substances which are suitable for enteral (for example oral), parenteral or topical application and do not react with the new compounds, for example water, vegetable oils (such as sunflower oil or Cod liver oil), benzyl alcohols, polyethylene glycols, gelatin, carbohydrates such as lactose or starch, magnesium stearate, talc, lanolin or petroleum jelly.
  • vegetable oils such as sunflower oil or Cod liver oil
  • benzyl alcohols polyethylene glycols
  • gelatin carbohydrates such as lactose or starch
  • magnesium stearate magnesium stearate
  • talc lanolin or petroleum jelly
  • solvents such as water, physiological saline or alcohols such as ethanol, propanol or glycerin, sugar solutions such as glucose or mannitol solutions or a mixture of the solvents mentioned, gel formers, tablet excipients and other excipients, for example lubricants, stabilizers and / or wetting agents, emulsifiers, salts for influencing osmotic pressure, antioxidants,
  • Dispersants for example one or more vitamins.
  • the invention also relates to a set consisting of separate packs of a) an effective amount of a compound of the formula I and / or its physiologically acceptable salts, derivatives, solvates and stereoisomers, including their mixtures in all ratios and b) an effective one Amount of another drug ingredient.
  • the set contains suitable containers, such as boxes or cartons, individual bottles, bags or ampoules.
  • the set can contain, for example, separate ampoules, each containing an effective amount of a compound of the formula I and / or its pharmaceutically acceptable derivatives, solvates, stereoisomers, including their mixtures in all ratios, and an effective amount of a further active pharmaceutical ingredient, dissolved or in lyophilized form is present.
  • Tablets, dragees, capsules, syrups, juices, drops or suppositories are used in particular for enteral administration (orally or rectally), solutions, preferably oily or aqueous solutions, furthermore suspensions, for parenteral administration (subcutaneously or intravenously),
  • Emulsions or implants for topical use ointments, creams, pastes, lotions, gels, sprays, foams, aerosols, solutions (e.g. solutions in alcohols such as ethanol or isopropanol, acetonitrile, DMF, dimethylacetamide, 1, 2-propanediol or their mixtures with one another and / or with water) or powder.
  • solutions e.g. solutions in alcohols such as ethanol or isopropanol, acetonitrile, DMF, dimethylacetamide, 1, 2-propanediol or their mixtures with one another and / or with water
  • Liposomal preparations are also particularly suitable for topical applications.
  • the compounds and / or their physiologically acceptable salts and solvates can also be lyophilized and the lyophilizates obtained can be used, for example, for the production of injectables. They can also be administered as nasal sprays.
  • the compounds according to the invention can be administered to humans or animals, in particular mammals, such as monkeys, dogs, cats, rats or mice, and can be used in the therapeutic treatment of the human or animal body and in combating the diseases listed above. They can continue to be used as diagnostics or as reagents.
  • the compounds according to the invention and / or their physiologically acceptable salts and solvates are generally used analogously to known, commercially available preparations or preparations, preferably in doses between 0.1 and 500 mg, in particular 5 and 300 mg per application unit.
  • the daily dosage is preferably between 0.001 and 250 mg / kg, in particular 0.01 and 100 mg / kg body weight.
  • the preparation can be administered one or more times a day, for example two, three or four times during the day.
  • the individual dosage for a patient depends on a large number of individual factors, such as, for example, the effectiveness of the compound used, the age, body weight, general health, gender, diet, the time and route of administration, the rate of excretion, the Combination with other drugs and the severity and duration of the disease. Oral application is preferred.
  • a measure of the absorption of an active pharmaceutical ingredient into an organism is its bioavailability. If the active pharmaceutical ingredient is administered intravenously to the organism in the form of a solution for injection, its absolute bioavailability, i.e. the proportion of the drug that remains unchanged in the systemic blood, i.e. enters the large cycle at 100%.
  • the active ingredient is usually present in the formulation as a solid and must therefore first dissolve so that it can overcome the entry barriers, for example the gastrointestinal tract, the oral mucosa, nasal membranes or the skin, in particular the stratum corneum or can be absorbed by the body.
  • Pharmacokinetic data i.e. Bioavailability can be obtained analogously to the method of J. Shaffer et al., J. Pharm. Sciences, 88 (1999), 313-318.
  • FAB Fluorescence Bombardment: (M + H) + THF (tetrahydrofuran), NMP (N-methyl pyrrolidone), DMSO (dimethyl sulfoxide), EE (ethyl acetate), MeOH (methanol), DC (thin layer chromatography)
  • 0.8 g (20 mmol) NaH is suspended in 20 ml THF and a solution of 4.6 g (20 mmol) 3- (4-chlorobutyl) -1 H-indole-5- at room temperature carbonitrile added dropwise in 50 ml of THF.
  • the yellow solution is stirred for 30 minutes and then a solution of 1.2 ml (20 mmol) iodomethane in 30 ml THF is added dropwise.
  • the yellow solution becomes 1 h at Room temperature stirred.
  • the reaction solution is then concentrated and the residue is shaken out with ethyl acetate and water.
  • the organic phase is washed with water, dried with sodium sulfate and concentrated.
  • the reaction mixture is stirred into 100 ml of water. Fine crystals precipitate out. These are suctioned off, washed with water and air-dried overnight. The resulting 0.9 g of light brown crystals are finally purified by chromatography to 0.8 g of light crystals. These are dissolved in hot acetone and mixed with one milliliter of ethanolic HCI. White crystals immediately fall out. These are stirred again while hot, suction filtered and washed with acetone.
  • a large number of the synthesized compounds have nanomolar affinity for the 5-HT ⁇ A receptors, as well as a nanomolar inhibition of serotonin reuptake.
  • a solution of 100 g of a compound of the formula I and 5 g of disodium hydrogenphosphate is adjusted to pH 6.5 in 3 l of double-distilled water with 2N hydrochloric acid, sterile filtered, filled into injection glasses, lyophilized under sterile conditions and sealed sterile. Each injection glass contains 5 mg of a compound of formula I.
  • Example 5 Suppositories
  • a mixture of 20 g of a compound of the formula I is melted with 100 g of soy lecithin and 1400 g of cocoa butter, poured into molds and allowed to cool.
  • Each suppository contains 20 mg of a compound of formula I.
  • a solution is prepared from 1 g of a compound of formula I, 9.38 g
  • Benzalkonium chloride in 940 ml of double distilled water. It is adjusted to pH 6.8, made up to 1 l and sterilized by irradiation. This solution can be used in the form of eye drops.
  • 500 mg of a compound of the formula I are mixed with 99.5 g of petroleum jelly under aseptic conditions.
  • a mixture of 1 kg of a compound of formula I, 4 kg of lactose, 1, 2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is compressed into tablets in a conventional manner such that each tablet contains 10 mg of a compound of Formula I contains.
  • Example 9 Dragees Analogously to Example E, tablets are pressed, which are then coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and colorant.
  • a solution of 1 kg of a compound of the formula I in 60 l of double-distilled water is sterile filtered, filled into ampoules, lyophilized under sterile conditions and sealed under sterile conditions. Each ampoule contains 10 mg of a compound of formula I.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Composés de formule (I), utilisation desdits composés pour produire un médicament destiné à traiter des maladies liées au récepteur de la sérotonine et / ou à la réabsorption de la sérotonine, en particulier pour produire un médicament de type anxiolytique, antidépresseur, neuroleptique et / ou antihypertonique et / ou pour influencer positivement les troubles obsessionnels-compulsifs, les troubles du sommeil, la dyskinésie tardive, les troubles de l'apprentissage, les troubles de la mémoire liés à l'âge, les troubles alimentaires tels que la boulimie et / ou le syndrome du colon irritable et / ou les troubles de la fonction sexuelle. Lesdits composés se lient au récepteur 5-HT1A.
EP04734520A 2003-06-16 2004-05-24 Derives d'indol en tant qu'inhibiteurs de reapsorption de la serotonine Withdrawn EP1633742A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10326940A DE10326940A1 (de) 2003-06-16 2003-06-16 Indol-Derivate
PCT/EP2004/005546 WO2004113325A1 (fr) 2003-06-16 2004-05-24 Dérivés d'indol en tant qu'inhibiteurs de réapsorption de la sérotonine

Publications (1)

Publication Number Publication Date
EP1633742A1 true EP1633742A1 (fr) 2006-03-15

Family

ID=33495050

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04734520A Withdrawn EP1633742A1 (fr) 2003-06-16 2004-05-24 Derives d'indol en tant qu'inhibiteurs de reapsorption de la serotonine

Country Status (12)

Country Link
US (1) US20060160824A1 (fr)
EP (1) EP1633742A1 (fr)
JP (1) JP2006527706A (fr)
KR (1) KR20060021896A (fr)
CN (1) CN1805954A (fr)
AR (1) AR044713A1 (fr)
AU (1) AU2004249371A1 (fr)
BR (1) BRPI0411456A (fr)
CA (1) CA2529298A1 (fr)
DE (1) DE10326940A1 (fr)
MX (1) MXPA05013537A (fr)
WO (1) WO2004113325A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10326939A1 (de) * 2003-06-16 2005-01-05 Merck Patent Gmbh Indol-Derivate
AU2006267338B2 (en) 2005-07-13 2012-08-16 Msd K.K. Heterocycle-substituted benzimidazole derivative
EP2110374A1 (fr) * 2008-04-18 2009-10-21 Merck Sante Dérivés de benzofurane, benzothiophène, benzothiazol en tant que modulateurs FXR
US8367676B2 (en) * 2009-06-30 2013-02-05 Astrazeneca Ab 2-carboxamide-7-piperazinyl-benzofuran derivatives 774
WO2012087229A1 (fr) * 2010-12-20 2012-06-28 Astrazeneca Ab Dérivé de 2-carboxamide-4-pipérazinyl-benzofurane
CN102993186B (zh) * 2012-12-20 2015-11-18 北京海步国际医药科技发展有限公司 一种新型的哌嗪衍生物
EP3027607B1 (fr) 2013-07-29 2020-08-26 Sunshine Lake Pharma Co., Ltd. Composés hétéroaryliques substitués et procédés d'utilisation
CN106243088B (zh) 2015-06-03 2019-01-04 广东东阳光药业有限公司 取代的哌嗪化合物及其使用方法和用途
US11285153B2 (en) 2017-09-29 2022-03-29 Sunshine Lake Pharma Co., Ltd. Substituted pyrimidine piperazine compound and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8830312D0 (en) * 1988-12-28 1989-02-22 Lundbeck & Co As H Heterocyclic compounds
DE4333254A1 (de) * 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
EP1007523B9 (fr) * 1997-07-25 2004-09-08 H. Lundbeck A/S Derives indole et 2,3-dihydro-indole, leur preparation et utilisation
DE10112151A1 (de) * 2001-03-14 2002-09-19 Merck Patent Gmbh Substituierte Benzofuran-2-carbonsäureamide
CA2450167A1 (fr) * 2001-06-12 2002-12-19 Elan Pharmaceuticals, Inc. Macrocycles utiles dans le traitement de la maladie d'alzheimer
UA76758C2 (uk) * 2001-06-19 2006-09-15 Мерк Патент Гмбх Поліморфні форми гідрохлориду 1-'4-(5-ціаноіндол-3-іл)бутил-4-(2-карбамоїлбензофуран-5-іл)піперазину
DE10259244A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh N-(Indolethyl-)cycloamin-Verbindungen
DE10326939A1 (de) * 2003-06-16 2005-01-05 Merck Patent Gmbh Indol-Derivate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004113325A1 *

Also Published As

Publication number Publication date
CN1805954A (zh) 2006-07-19
MXPA05013537A (es) 2006-03-09
BRPI0411456A (pt) 2006-07-18
CA2529298A1 (fr) 2004-12-29
DE10326940A1 (de) 2005-01-05
AR044713A1 (es) 2005-09-21
US20060160824A1 (en) 2006-07-20
KR20060021896A (ko) 2006-03-08
AU2004249371A1 (en) 2004-12-29
WO2004113325A1 (fr) 2004-12-29
JP2006527706A (ja) 2006-12-07

Similar Documents

Publication Publication Date Title
EP0648767B1 (fr) Dérivés de piperidine et piperazine qui puissent agir sur le "CNS"
DE69513219T2 (de) Kondensierte heterocyclische Verbindungen, ihre Herstellung und Anwendung
DE69909818T2 (de) Pyrazolopyimidinon-derivate zur behandlung von impotenz
EP0736525B1 (fr) Benzonitriles comme 5-HT agonistes et antagonistes
DE10315572A1 (de) Substituierte Pyrazole
DE69015322T2 (de) Substituierte Zyklobutendion-Verbindungen.
EP1611107B1 (fr) Pyrazoles substitues en position 1,3 et 4 utilises en tant qu'antagonistes des recepteurs 5-ht pour le traitement de psychoses et de troubles neurologiques
EP1633741A1 (fr) Derives d'indole en tant qu'inhibiteurs de la recapture de la serotonine
EP1611094B1 (fr) Composes pyrazole
EP1633742A1 (fr) Derives d'indol en tant qu'inhibiteurs de reapsorption de la serotonine
EP1594864B1 (fr) Benzofuranoxyethylamines servant d'antidepresseurs et d'anxiolytiques
EP0415065A1 (fr) Dérivés de chromane
EP1562596B1 (fr) Derives de pyridinalkyl-aminoalkyl-1h-indole inhibant les recepteurs 5-ht et la recapture de la serotonine, pouvant servir d'antidepresseurs et d'anxiolytiques
EP0406656A1 (fr) Dérivés de chromane
EP0489327A1 (fr) Dérivés de chromanne
EP1592687B1 (fr) Derives de benzofurane et leur utilisation en tant qu'antidepresseurs et anxiolytiques
EP0560399A1 (fr) Utilisation des 3,4-dihydro-2H-benzopyranes substitués comme médicament contre des maladies de l'urètre
DE69008565T2 (de) Aminoalkoxyphenyl-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Zusammensetzungen.
DE19904406A1 (de) Substituierte Pyrazolcarbonsäuren
WO2005082886A1 (fr) Derives de piperidine
DE10360151A1 (de) Azoverbindungen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051020

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: LT LV

17Q First examination report despatched

Effective date: 20060803

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20051020

Extension state: LT

Payment date: 20051020

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070214